PMN ProMIS: Enterprise Value to EBITDA Ratio

This daily price chart for ProMIS Neurosciences (PMN) reflects an EV/EBITDA ratio of 0.00. ProMIS Neurosciences develops specific antibodies to combat dementia, generating sustainable solvent demand over the long term. Its high-tech production is based on a selective approach to neuron therapy. Authoritative management ensures the success of the business model by effectively advancing innovative developments through the stages of clinical trials.

PMN ProMIS Neurosciences Inc.: Business Value to Operating Income Before Depreciation in the range 11/23/2025 - 11/10/2026

promisneurosciences.com (PMN) - metric breakdowns and financial figures

- current price and projected stock value:

Stock Price ProMIS Neurosciences, Inc.|PMN - Average Forecast Price

- company stock capitalization data:

Market Valuation ProMIS Neurosciences, Inc.|PMN - Enterprise Value

- business book valuation details:

Net Assets per Single Share ProMIS Neurosciences|PMN - Accounting Value of Company|Market Value to Book Value Ratio promisneurosciences.com|PMN - Company Assets

- issuer credit burden and liquidity indicators:

- business earnings and investment ratios data:

PMN - Profit After Tax|Expected Profit ProMIS Neurosciences|PMN - Company Value to Net Income|Future Price to Earnings ProMIS Neurosciences, Inc.|PMN - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ProMIS Neurosciences, Inc.|PMN - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) ProMIS Neurosciences|PMN - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months promisneurosciences.com|PMN - Expected net earnings per share growth this year|Expected earnings per share growth for next year ProMIS Neurosciences

Initial company analysis:ProMIS PMN

Original product of ProMIS Neurosciences, Inc.

Scaling the expansion of PMN310 antibodies requires significant capital expenditures; therefore, the EV/EBITDA multiple history of the business allows for an objective valuation of ProMIS Neurosciences (PMN) assets, accounting for the debt load. This indicator compares total market capitalization and loans against operating profit before taxes, helping investors identify excessive leverage risks and determine the issuer's financial stability.

Main competitors